Iquix

Plague, Yersinia pestis, inhaled anthrax caused by Bacillus anthracis + 21 more
Treatment
1 FDA approval
9 Active Studies for Iquix

What is Iquix

LevofloxacinThe Generic name of this drug
Treatment SummaryLevofloxacin is an antibiotic used to treat various bacterial infections. It is 8 to 128 times more effective against both gram-negative and gram-positive bacteria than its predecessor, ofloxacin. This medication is a part of the third generation of fluoroquinolones, which are often referred to as "respiratory quinolones" due to their effectiveness in treating respiratory infections. Levofloxacin was approved by the FDA in 1996 and is also available in Canada and other South American countries.
Levaquinis the brand name
image of different drug pills on a surface
Iquix Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Levaquin
Levofloxacin
1996
421

Approved as Treatment by the FDA

Levofloxacin, also known as Levaquin, is approved by the FDA for 1 uses like Pseudomonas Infections .
Pseudomonas Infections
Used to treat Nosocomial Pneumonia caused by Pseudomonas Infections in combination with Piperacillin

Effectiveness

How Iquix Affects PatientsLevofloxacin is an antibiotic that works by blocking the bacteria's ability to make new DNA, which stops it from reproducing. This drug usually requires only one or two doses a day, but can cause an abnormal heart rhythm in some patients, so it should be used carefully in people with other risk factors, like low potassium levels. It has been found to work against certain types of bacteria, as well as some other kinds of germs like Chlamydia and Legionella. It is possible for bacteria to become resistant to levofloxacin, but it is unlikely to become resistant to other kinds of antibiotics.
How Iquix works in the bodyLevofloxacin is an antibiotic that fights bacteria by blocking two bacterial enzymes. These enzymes, called DNA gyrase and topoisomerase IV, help bacteria reproduce and survive. Levofloxacin stops these enzymes from working, which prevents the bacteria from dividing and growing. This leads to the death of the bacteria.

When to interrupt dosage

The measure of Iquix is contingent upon the recognized ailment, including Pseudomonas Infections, Abscess and Therapeutic process. The amount of dosage is contingent upon the technique of delivery outlined in the table below.
Condition
Dosage
Administration
Yersinia pestis
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Cystic Fibrosis
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Pseudomonas Infections
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Impetigo
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Wound Infection
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Community Acquired Pneumonia (CAP) caused by susceptible bacteria
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
furuncle
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Pyoderma
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Hospital acquired pneumonia
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Communicable Diseases
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Cellulitis
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Abscess
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Prostatitis
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Pseudomonas Infections
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Communicable Diseases
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Sinusitis
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Urinary tract infection
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Bacterial conjunctivitis
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Therapeutic procedure
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral
Plague
250.0 mg, 500.0 mg, 750.0 mg, , 5.0 mg/mL, 25.0 mg/mL, 15.0 mg/mL, 7.5 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 240.0 mg, 240.0 mg/mL
, Tablet, film coated, Oral, Tablet, film coated - Oral, Ophthalmic, Solution / drops, Solution, Solution / drops - Ophthalmic, Solution - Oral, Injection - Intravenous, Injection, Solution - Ophthalmic, Solution - Intravenous, Tablet, Intravenous, Injection, solution - Intravenous, Injection, solution, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Topical, Solution / drops - Topical, Respiratory (inhalation), Solution - Respiratory (inhalation), Tablet - Oral

Warnings

Iquix has one contraindication, so its use should be avoided when faced with the conditions indicated in the table below.Iquix Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Levofloxacin may interact with Pulse Frequency
There are 20 known major drug interactions with Iquix.
Common Iquix Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Levofloxacin.
Amiodarone
Major
The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amiodarone.
Amitriptyline
Major
Levofloxacin may increase the QTc-prolonging activities of Amitriptyline.
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Arsenic trioxide.
Iquix Toxicity & Overdose RiskLevofloxacin is low in toxicity, yet an overdose can lead to ataxia, drooping eyelids, decreased movement, difficulty breathing, shaking, and seizures. Treatment for an overdose should include emptying the stomach and providing supportive care. It may also be helpful to monitor the patient's heart rate and rhythm. Dialysis is not an effective way to remove levofloxacin from the body.

Iquix Novel Uses: Which Conditions Have a Clinical Trial Featuring Iquix?

Condition
Clinical Trials
Trial Phases
Bronchitis
8 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2
Wound Infection
0 Actively Recruiting
inhaled anthrax caused by Bacillus anthracis
0 Actively Recruiting
Prostatitis
0 Actively Recruiting
Cellulitis
0 Actively Recruiting
Pseudomonas Infections
0 Actively Recruiting
Pseudomonas Infections
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Urinary tract infection
0 Actively Recruiting
Hospital acquired pneumonia
0 Actively Recruiting
Sinusitis
0 Actively Recruiting
Yersinia pestis
0 Actively Recruiting
Plague
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Pyoderma
1 Actively Recruiting
Phase 2
Impetigo
0 Actively Recruiting
furuncle
0 Actively Recruiting
Community Acquired Pneumonia (CAP) caused by susceptible bacteria
0 Actively Recruiting
Urinary tract infection
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting

Iquix Reviews: What are patients saying about Iquix?

5Patient Review
5/22/2008
Iquix for Ulcer of the Cornea of the Eye with Bacterial Infection
I had an infection in the back of my eye. The symptoms were gone in one day.
1Patient Review
11/22/2009
Iquix for Ulcer of the Cornea of the Eye with Bacterial Infection
I've been using this medication for three weeks now, and I'm not seeing any results. I have a parasite in my eye and I wonder if there's something else out there that could help me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about iquix

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is levofloxacin eye drops used for?

"Ophthalmic levofloxacin is used in the eye to treat bacterial infections of the eye. Ophthalmic levofloxacin works by killing bacteria. This medicine is available only with a prescription from your doctor."

Answered by AI

Is levaquin isotonic?

"This is a dilute solution of levofloxacin in 5% dextrose solution. It is non-pyrogenic and nearly isotonic."

Answered by AI

How to use eye drops?

"To use eye drops correctly, tilt your head back and look up. Use one hand to pull your lower eyelid down and away from your eyeball. This will form a pocket. Hold the eye drop bottle upside down in the other hand with the tip just above the pocket. Squeeze the prescribed number of drops into the pocket."

Answered by AI

Clinical Trials for Iquix

Image of McGill University Health Centre in Montreal, Canada.

Oscillatory Positive Expiratory Pressure Therapy for COPD

18+
All Sexes
Montreal, Canada
The goal of this non-pharmacologic interventional study is to learn if Oscillatory Positive Expiratory Pressure (OPEP) therapy can improve disease impact and respiratory system dynamics in patients with COPD. The main questions it aims to answer are: Is OPEP therapy able to improve the impact of cough symptoms as measured on a validated symptom score? Is OPEP therapy able to improve the properties of the lung (called reactance) as measured by oscillometry? Researchers will compare the results of the same tests performed before and after 4 weeks of OPEP treatment to see if OPEP treatment improves cough symptoms and lung mechanics. * Participants with COPD will complete in-person baseline tests and will then receive the smart OPEP device. * These participants will then use the smart OPEP device at home, at least twice a day, for 4 consecutive weeks. * Finally, these participants will return to complete in-person end-of-study tests.
Recruiting
Has No Placebo
McGill University Health CentreBryan A. Ross, MD, MSc (Physiol), MSc (Epi)Trudell Medical International
Have you considered Iquix clinical trials? We made a collection of clinical trials featuring Iquix, we think they might fit your search criteria.Go to Trials
Image of El Camino Hospital in Mountain View, United States.

RejuvenAir System for Chronic Bronchitis

40 - 80
All Sexes
Mountain View, CA
Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis (CB) is a common clinical phenotype within the umbrella of a COPD diagnosis and is classically defined as chronic cough and sputum production for 3 months a year for 2 consecutive years2, but many studies have used different definitions to define it- chronic cough and sputum production for one year or cough and sputum production on most days of the week. CB is associated with multiple clinical consequences, including; the worsening of lung function decline, increasing risk of acute exacerbations of COPD, increased risk of developing pneumonia, reduced health related quality of life, and an increase in all-cause mortality.
Waitlist Available
Quick Reply
Device
El Camino Hospital (+26 Sites)Gerard Criner, MDCSA Medical, Inc.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security